New Treatment Offers Hope for Children with Dravet Syndrome, Reducing Seizures by Up to 91%

A new experimental treatment is showing significant promise in reducing seizures for children with Dravet syndrome, a rare and severe form of epilepsy. Researchers at University College London (UCL) have developed a therapy that, in clinical trials, decreased seizure frequency by as much as 91%.

Dravet syndrome is a genetic epileptic encephalopathy that begins in infancy, characterized by difficult-to-control seizures and neurodevelopmental disorders. Epilepsy Foundation

Understanding the Genetic Basis of Dravet Syndrome

The research team focused on the underlying cause of Dravet syndrome: a defect in the SCN1A gene. Individuals with this disorder often have only one functional copy of the gene, leading to insufficient production of a protein crucial for proper nerve cell function. CNS Drugs

Zorevunersen: Restoring Protein Levels

The newly developed treatment, called zorevunersen, is designed to increase the levels of the protein produced by the healthy SCN1A gene. In a clinical trial involving 81 children aged 2 to 18, participants initially experienced an average of 17 epileptic seizures per month. CNS Drugs

Participants received up to 70 mg of zorevunersen, with some receiving additional doses over a six-month period. Following the initial trial, 75 children continued to collaborate with researchers and received the treatment every four months.

Significant Reduction in Seizure Frequency

Results demonstrated a substantial decrease in seizure frequency. Over the first 20 months of treatment, patients experienced a reduction in seizures ranging from 59% to 91% compared to their baseline seizure rates. The treatment also showed improvements in quality of life for both patients and their families. CNS Drugs

One mother, whose 8-year-old son participated in the study, reported a dramatic change in his condition, going from more than a dozen seizures nightly to just one or two brief seizures every three to five days.

Zorevunersen: Safety and Ongoing Trials

Zorevunersen has demonstrated a favorable safety profile and has been well-tolerated by most patients. Lead author Helen Cross emphasized the demand for “further evaluation as part of the ongoing phase three study.” CNS Drugs

Phase III trials are currently underway to assess the therapeutic benefit of zorevunersen on a larger scale, evaluating its usefulness, effectiveness and potential adverse effects.

Diagnosing and Treating Dravet Syndrome

Early and accurate diagnosis of Dravet syndrome is crucial for effective management. Diagnosis typically involves evaluating clinical presentation, EEG findings, MRI results, and genetic testing. Dravet Syndrome Foundation

Treatment strategies often involve a combination of anti-seizure medications, with careful consideration given to the specific needs of each patient. Dravet Syndrome Foundation

Dravet syndrome, previously known as severe myoclonic epilepsy of infancy (SMEI), is a rare and serious type of epilepsy where the first seizure often happens with a high fever and can last more than five minutes. Cleveland Clinic